Theravance Biopharma. has been granted a patent for compounds that inhibit neprilysin, along with related pharmaceutical compositions and methods for their use. The patent includes a specific method for treating diseases associated with neprilysin by administering these compounds to affected subjects. GlobalData’s report on Theravance Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Theravance Biopharma, was a key innovation area identified from patents. Theravance Biopharma's grant share as of June 2024 was 65%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12016835B2 outlines a method for treating diseases associated with neprilysin in subjects requiring intervention. The method involves administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and an effective amount of a specific compound, referred to as formula (Ma). The patent specifies that the diseases targeted by this treatment may include cardiovascular diseases, renal diseases, glaucoma, diarrhea, and pain, with particular emphasis on conditions such as hypertension and heart failure within the cardiovascular category.
Additionally, the patent details the potential for combination therapy, allowing for the administration of various therapeutic agents alongside the primary compound. These agents encompass a wide range of drug classes, including adenosine receptor antagonists, various adrenergic receptor antagonists and agonists, aldosterone antagonists, and numerous others aimed at addressing specific symptoms or underlying mechanisms of the diseases mentioned. The claims also specify particular structural characteristics of the compound of formula (Ma), including variations in substituents and functional groups, which may influence its therapeutic efficacy. Overall, the patent presents a comprehensive approach to treating neprilysin-mediated diseases through targeted pharmacological intervention.
To know more about GlobalData’s detailed insights on Theravance Biopharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
